2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

Catalog No. :
ACOGZN684
CAS No. :
2223040-81-9
Molecular Formula :
C13H21BN2O2
Molecular Weight :
248.13

IUPAC Name:2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine

2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$566.00Login to see priceInquiryInquiry
250mg98%$755.00Login to see priceInquiryInquiry
1g98%$1887.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
IUPAC Name2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
MDL No.MFCD11223344
Molecular FormulaC13H21BN2O2
Molecular Weight248.13
SMILESCC(C)C1=NC=C(B2OC(C)(C)C(C)(C)O2)N=C1
InChI KeyXCXXTYCGZKBOIV-UHFFFAOYSA-N
Synonym2-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine;Pyrazine, 2-(1-methylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2223040-81-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACOGZN684 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCUSA641 route compound structure diagram
    ACCUSA6411086382-76-4 In Stock
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACOGZN684 route product structure diagram
    ACOGZN6842223040-81-9
Inquiry

2. ACOGZN684 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOGZN684 route product structure diagram
    ACOGZN6842223040-81-9
Inquiry

Comments (0)